Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 9/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6321194 | 0.83 | DYRK1A (0.42) | EGLN2DYRK1ASCN5ATGFBR1KDM1A | |
| SCHEMBL6315893 | 0.75 | DYRK1A (0.40) | EGLN2DYRK1ASCN5ATGFBR1KDM1A | |
| SCHEMBL6316118 | 0.75 | GRM5 (0.44) | EGLN2DYRK1ASCN5ATGFBR1 | |
| SCHEMBL1994499 | 0.71 | PDE10A (0.39) | EGLN2 | |
| SCHEMBL9903810 | 0.70 | KIT (0.43) | TGFBR1 | |
| SCHEMBL6316340 | 0.70 | CA12 (0.41) | EGLN2 | |
| SCHEMBL6322242 | 0.70 | GRM5 (0.49) | DYRK1ATGFBR1 | |
| SCHEMBL3326856 | 0.69 | DYRK1A (0.47) | DYRK1ASCN5ATGFBR1PIK3CDMAP4K4 | |
| SCHEMBL3326861 | 0.69 | DYRK1A (0.47) | EGLN2DYRK1ASCN5ATGFBR1PIK3CD | |
| SCHEMBL18077230 | 0.69 | SCN5A (0.47) | EGLN2DYRK1ASCN5ATGFBR1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124509-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | Clavius Pharmaceuticals, LLC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200239462-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS, LLC | 2020-07-30 | — | — | US | disclosed |
| WO-2019005241-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS, LLC (US) | 2019-01-03 | — | — | WO | disclosed |
| EP-2513102-B1 | ETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-8933094-B2 | Ethynyl compounds useful for treatment of CNS disorder | HOFFMANN-LA ROCHE INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140073638-A1 | ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDER | HOFFMANN-LA ROCHE INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8586581-B2 | Ethynyl compounds useful for treatment of CNS disorders | Hoffmann-La Roche Inc (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2513102-A1 | ETHYNYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20110152257-A1 | ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDERS | HOFFMANN-LA ROCHE, INC. | 2011-06-23 | — | — | US | disclosed |
| WO-2011073172-A1 | ETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20050014938-A1 | Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase | GASTER LARAMIE MARY (GB) | 2005-01-20 | — | — | US | disclosed |
| US-20040220230-A1 | Pyridinylimidazoles | SMITHKLINE BEECHAM P.L.C. | 2004-11-04 | — | — | US | disclosed |
| EP-1444227-A1 | THIAZOLYL SUBSTITUTED TRIAZOLES AS ALK5 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040152738-A1 | Pyridyl-substituted triazoles as tgf inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| US-20030166633-A1 | Pyridinylimidazoles | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-09-04 | — | — | US | disclosed |
| EP-1335916-A1 | PYRIDYL-SUBSTITUTED TRIAZOLES AS TGF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003042207-A1 | THIAZOLYL SUBSTITUTED TRIAZOLES AS ALK5 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-22 | — | — | WO | disclosed |
| EP-1257543-A1 | PYRIDINYLIMIDAZOLES | SMITHKLINE BEECHAM PLC (GB) | 2002-11-20 | — | — | EP | disclosed |
| WO-2002040476-A1 | PYRIDYL-SUBSTITUTED TRIAZOLES AS TGF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2001062756-A1 | PYRIDINYLIMIDAZOLES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014938-A1 | Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase | AKR1C3, CBR3, PHKG1 | EGLN2 1981/4885DYRK1A 847/4885SCN5A 595/4885 |
| US-20030166633-A1 | Pyridinylimidazoles | NR0B1, NR1I2, NR0B2 | EGLN2 2548/4885DYRK1A 1633/4885SCN5A 805/4885 |
| US-11124509-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | TGFB1, TGFBR1, TGFB2 | EGLN2 543/4885DYRK1A 2769/4885SCN5A 2937/4885 |
| US-20110152257-A1 | ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDERS | GRM5, GRIK5, GRM1 | EGLN2 3685/4885DYRK1A 1777/4885SCN5A 115/4885 |
| US-20040152738-A1 | Pyridyl-substituted triazoles as tgf inhibitors | TGFBR1, TGFBR2, SMAD3 | EGLN2 1005/4885DYRK1A 3544/4885SCN5A 554/4885 |
| US-20040220230-A1 | Pyridinylimidazoles | NR0B1, NR1I2, NR0B2 | EGLN2 2618/4885DYRK1A 1644/4885SCN5A 839/4885 |
| US-20200239462-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | TGFB1, TGFBR1, TGFB2 | EGLN2 543/4885DYRK1A 2769/4885SCN5A 2937/4885 |
| US-20140073638-A1 | ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDER | GRM5, GRIK5, GRM1 | EGLN2 3731/4885DYRK1A 1846/4885SCN5A 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.